Xenidis N.,University General Hospital of Alexandroupolis |
Kotsakis A.,University General Hospital of Heraklion |
Kalykaki A.,University General Hospital of Heraklion |
Christophyllakis C.,Medical Oncology Unit |
And 8 more authors.
Lung Cancer | Year: 2010
Purpose: The combination of irinotecan and cisplatin (IP) has shown at least comparable efficacy to that of etoposide/cisplatin (EP) in patients with extensive-stage small cell lung cancer. We conducted a phase II study to evaluate the efficacy and tolerance of EP regimen followed by thoracic radiotherapy (TRT) and IP consolidation chemotherapy in patients with limited-stage small cell lung cancer. Patients and methods: Thirty-three chemotherapy-naive patients with limited-stage small cell lung cancer (LS-SCLC) were treated with etoposide 100mg/m2 on days 1-3 and cisplatin 80mg/m2 on day 1. Radiotherapy was given 3 weeks after the first treatment cycle concurrently with weekly cisplatin 20mg/m2 on day 1 and etoposide 50mg/m2 on day 4 within 5-6 weeks, followed by three courses of irinotecan 60mg/m2 on days 1, 8, and 15 and cisplatin 60mg/m2 on day 1 of a 4-week cycle. Results: There were no treatment-related deaths. Toxicities during chemo-radiotherapy were mild including grade 3/4 neutropenia (24%) and grade 2 esophagitis (6%). The major toxicity observed during consolidation chemotherapy was grades 3-4 neutropenia which affected 42% of patients. In an intention-to-treat analysis the overall response rate was 66% (CR: 30% and PR: 36%). After a median follow-up period of 35.7 months (range: 9.6-41.2 months), the median survival time was 19 months (95% CI: 14.5-23.5 months), the median time to tumor progression 8.3 months and the 1- and 2-year survival rates 72% and 27.5%, respectively. Conclusions: Consolidation chemotherapy with IP following concurrent EP plus TRT is a safe and with acceptable toxicity regimen and deserves further phase III testing in patients with LS-SCLC. © 2009 Elsevier Ireland Ltd.
Galanopoulos G.,IASO General Hospital of Athens
Il Giornale di chirurgia | Year: 2011
Sudden sensorineural hearing loss following non-otologic surgery, under general anesthesia, is an extremely rare complication. Furthermore, postoperative deafness has more commonly been associated with cardiac surgery. This acute dysfunction of the inner ear consists a controversial subject in terms of etiopathogenic mechanisms and treatment modalities. We present the case of a 60-year-old male patient who underwent varicose vein surgery under general anesthesia and presented immediately after the operation bilateral and profound impairment of his hearing acuity. A high index of suspicion is required to early diagnosis of this complication, although prompt treatment does not guarantee a good outcome.
Xenidis N.,University General Hospital of Alexandroupolis |
Vardakis N.,University of Crete |
Varthalitis I.,Agios Georgios General Hospital of Chania |
Giassas S.,IASO General Hospital of Athens |
And 6 more authors.
Cancer Chemotherapy and Pharmacology | Year: 2011
Purpose: To evaluate efficacy and toxicity of a combination of pegylated liposomal doxorubicin and irinotecan in patients with refractory small-cell lung cancer. Patients and methods: Thirty-one patients with early relapse after first-line therapy with cisplatin/etoposide were treated with pegylated liposomal doxorubicin 15 mg/m2 and irinotecan 125 mg/m2 on days 1 and 15. Treatment was repeated every 28 days. Results: A total of 144 chemotherapy courses were administered. All patients were evaluable for toxicity and twenty-six (84%) for response. Grade 3 neutropenia occurred in two (6.5%) patients and grade 1 thrombocytopenia in one (3.2%). Fatigue was the most frequent grade 3 non-hematologic toxicity and was observed in seven patients (23%). Four (12.9; 95% CI: 1.1-24.7%) patients achieved a partial response, and disease stabilization was observed in additional two (6.5%) patients (Tumor Growth Control: 19.4; 95% CI: 5.5-33.3%). The median TTP was 2.03 months, and the median survival time was 3.16 months. Conclusions: The combination of pegylated doxorubicin and irinotecan is very well tolerated but with modest activity in patients with refractory SCLC. © 2010 Springer-Verlag.
Galanopoulos G.,National and Kapodistrian University of Athens |
Lambidis C.,IASO General Hospital of Athens
Renal Failure | Year: 2014
Synthetic arteriovenous grafts for hemodialysis constitute the second choice in comparison with native arteriovenous fistulas. Lower patency rates and significantly more frequent infections are the main disadvantages of hemodialysis grafts over fistulas. Infectious complications could vary between a simple local erythema at a puncture site that resolves easily with antibiotics to septicemia and death. As a corollary, this kind of complications continue to be among the most important causes of morbidity and mortality in end-stage renal disease patients receiving long-term hemodialysis. The cornerstone is prevention of infections. It is generally accepted that following simple measures during the intervention of graft insertion and consecutively in every hemodialysis session could consistently reduce the risk of infection. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.
Kotoulas C.,IASO General Hospital of Athens
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Università di Napoli, Secondo ateneo | Year: 2011
Post-coarctation surgical repair aneurysm formation is observed rarely with end-to-end anastomosis technique. The redo surgery is associated with high mortality and morbidity rate. Although the minimal invasive method with stented grafts has been reported in only small number of patients, this could represent a valid alternative treatment. We present a case of successful endovascular treatment of a patient with a late post-coarctation repair saccular aneurysm.